CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the hereditary angioedema (HAE) candidate KVD900. “Thanks to our recent equity financing and the exciting Phase 1 data from KVD900, we are pleased to announce that we are building on these successes with a more aggressive develop